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Background: EndoPredict (EP) is a clinically validated multianalyte gene expression test to predict distant
metastasis in ER-positive, HER2-negative breast cancer treated with endocrine therapy alone. The test is based on
the combined analysis of 12 genes in formalin-fixed, paraffin-embedded (FFPE) tissue by reverse
transcription-quantitative real-time PCR (RT-qPCR). Recently, it was shown that EP is feasible for reliable
decentralized assessment of gene expression. The aim of this study was the analytical validation of the performance
characteristics of the assay and its verification in a molecular-pathological routine laboratory.
Methods: Gene expression values to calculate the EP score were assayed by one-step RT-qPCR using RNA from
FFPE tumor tissue. Limit of blank, limit of detection, linear range, and PCR efficiency were assessed for each of the
12 PCR assays using serial samples dilutions. Different breast cancer samples were used to evaluate RNA input
range, precision and inter-laboratory variability.
Results: PCR assays were linear up to Cq values between 35.1 and 37.2. Amplification efficiencies ranged from 75%
to 101%. The RNA input range without considerable change of the EP score was between 0.16 and 18.5 ng/μl.
Analysis of precision (variation of day, day time, instrument, operator, reagent lots) resulted in a total noise
(standard deviation) of 0.16 EP score units on a scale from 0 to 15. The major part of the total noise (SD 0.14) was
caused by the replicate-to-replicate noise of the PCR assays (repeatability) and was not associated with different
operating conditions (reproducibility). Performance characteristics established in the manufacturer’s laboratory were
verified in a routine molecular pathology laboratory. Comparison of 10 tumor samples analyzed in two different
laboratories showed a Pearson coefficient of 0.995 and a mean deviation of 0.15 score units.
Conclusions: The EP test showed reproducible performance characteristics with good precision and negligible
laboratory-to-laboratory variation. This study provides further evidence that the EP test is suitable for decentralized
testing in specialized molecular pathological laboratories instead of a reference laboratory. This is a unique feature
and a technical advance in comparison with existing RNA-based prognostic multigene expression tests.
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EndoPredict (EP) is a multigene assay which predicts the
risk of distant metastasis in ER+/HER2- breast cancer
and identifies a subgroup of patients who have an excel-
lent prognosis if treated with endocrine therapy alone
[1]. The test is based on the assessment of expression of
8 informative genes, 3 reference genes, and one gene to
measure the presence of genomic DNA in RNA from
formalin-fixed, paraffin-embedded (FFPE) tissue from
biopsies or surgical specimens using reverse transcription-
quantitative real-time PCR (RT-qPCR) [1-3]. Relative gene
expression levels are used to calculate the EndoPredict
score (EP score) ranging from 0 to 15. Patients with a score
below or equal to 5 are classified as low risk for distant
recurrence under endocrine therapy, those with a score
above 5 as high risk.
Translation of the EP test from research laboratory to
clinical practice covered the necessary steps for develop-
ment of a laboratory test (Figure 1). This included
method development for standardized RNA extraction
from FFPE tissue [4-6] and transfer of RT-qPCR assays
to a certified routine diagnostic platform [2,7] as well as
a discovery phase with biomarker identification and
training of an algorithm in a multicenter cohort [1].
Following discovery the pre-defined, locked-down EP
score was clinically validated in two separate cohorts
from the two randomized clinical trials ABCSG-6
(n=378) and ABCSG-8 (n=1324) [1]. Moreover, it has
been shown that the EP score provided prognostic infor-
mation on the risk of distant metastasis of breast cancerFigure 1 Translation of the EndoPredict multigene expression test fro
discovery and clinical as well as analytical validation is shown.patients beyond clinic-pathological parameters such as
ki-67 and quantitative ER immunohistochemistry [1].
Besides EndoPredict, other prognostic multigene
expression tests for patients with breast cancer like
MammaPrint [8], Oncotype DX [9,10], or PAM50
[11,12] are commercially available. However, all these
different tests can only be performed in reference
laboratories. In contrast, EndoPredict is suitable for
decentralized testing in specialized molecular pathological
laboratories as recently shown in a prospective analytical
proficiency testing program with seven different molecular
pathological laboratories [2].
The aim of this study was a comprehensive analytical
validation of the EP test to complete development before
implementation in clinical practice. Analytical validation
of multianalyte assays is still a challenge, as these types of
assays require a more complex evaluation of the perform-
ance characteristics compared with single analyte assays
in order to assure reliable performance in the clinical
routine. Adequate performance evaluation includes the
control of the process from the acquisition of the
tumor samples and isolation of the RNA to the assess-
ment of each single analyte as well as the combination of
the single results to a comprehensive score by an algo-
rithm. Moreover, guidelines for analytical validation of
multianalyte genomic assays are rare. Here, we analytically
validated the EndoPredict multianalyte gene expression assay
according to the adapted guideline MM17-A of the Clinical
and Laboratory Standards Institute (CLSI) addressing the
analytical validation of nucleic acid-based qualitative andm research laboratory to clinical practice. Workflow of sequential
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performance characteristics of the assay were verified in an
independent molecular pathological laboratory to confirm
that the test meets its specifications when used in a routine
diagnostic laboratory.Methods
Reference and Testing Materials
Nucleic acids for test development and validation were
selected based on the specific purpose of the respective
analytical performance characteristics to be tested. Sam-
ple material was comparable to the specimen used in the
clinical testing, i.e. DNA-free total RNA or genomic
DNA from FFPE tissue which is fragmented to nucleic
acid pieces by formalin-fixation [5,14]. Details about
reference nucleic acids are described in supplemental
data (see Additional file 1). In brief, for assessment of
limit of detection (LoD), linear range, and efficiency of
the single PCR assays large pools of control RNA and
control DNA from different FFPE tumor blocks were
generated and used for the experiments [15]. For the
precision studies, three tumor specimens classified by
the EP as low risk, high risk or close to the decision
point were selected. For the correlation study, ten tumor
samples were chosen with EP scores spanning the larger
part of the full score range. These ten tumor samples
were different to the ten samples used in the recently
published EndoPredict proficiency testing [2]. This study
was carried out in compliance with the Helsinki Declaration
and was approved by the Ethics Committee of the Charité
Hospital (Ref. No. EA1/139/05, Amendment 2008).
As positive controls of RT-qPCR assays a standardized
reference RNA (Stratagene qPCR Human Reference
Total RNA, Agilent Technologies, Böblingen, Germany)
and Human Genomic DNA (Roche Applied Bioscience,
Mannheim, Germany) were tested on each plate.Isolation of RNA and DNA
Total RNA and DNA was extracted from FFPE tissue
sections (10 μm) using a fully-automated silica-coated
magnetic bead-based method in combination with a liquid
handling robot (VERSANT Tissue Preparation System,
Siemens Healthcare Diagnostics, Eschborn, Germany) as
published previously [4-6].
The mean of Cq (quantification cycle) values of the EP
reference genes RPL37A, CALM2 and OAZ1 was used as
surrogate marker for mRNA yield following isolation. Con-
centration of total RNA was assessed using the QUANT-iT
RIBOGREEN assay (Life Technologies, Darmstadt,
Germany). For assessment of contamination with residual
DNA in RNA preparations, an HBB gene-specific quanti-
tative PCR was performed. Samples were considered to
be substantially free of DNA when Cq values above 38were detected. In case of DNA contamination samples
were manually re-digested by DNase I treatment.
Gene expression analysis using RT-qPCR
Expression of 8 genes-of-interest (AZGP1, BIRC5,
DHCR7, IL6ST, MGP, RBBP8, STC2, UBE2C) and three
reference genes (CALM2, OAZ1, RPL37A) as well as the
amount of residual genomic DNA (HBB) were assessed
by the EndoPredict assay (Sividon Diagnostics, Cologne,
Germany) as previously described [1,2]. This assay is
configured on a 96-well plate containing primers and
FAM/TAMRA-labeled hydrolysis probes dried into the
wells. Functional details about genes, data base accession
numbers and sequences of primers and probes were
published previously [1]. Gene expression was assessed by
one-step RT-qPCR using the SuperScript III PLATINUM
One-Step Quantitative RT-PCR System with ROX (Life
Technologies, Darmstadt, Germany) according to manufac-
turer’s instructions in a VERSANT kPCR Molecular System
(Siemens Healthcare Diagnostics, Eschborn, Germany) with
30 min at 50°C, 2 min at 95°C followed by 40 cycles of 15
sec at 95°C and 30 sec at 60°C. 20 μl reaction mix contain-
ing buffer, nucleotides, 4.5 mM Mg2+, enzymes and 1 μl
sample RNA, respectively, were added to each well. The
gene-specific reverse PCR primers were used as primers for
reverse transcription. Since the HBB-specific assay did not
target mRNA sequences the RT-qPCR protocol as
described above could be used all the same.
For calculation of the EP score genes were measured
in triplicates. This is mandatory to control for PCR
imprecision and to enable outlier removal [1,2]. Cq
values were calculated by the VERSANT kPCR Molecular
System software using amplification-based thresholds
following baseline correction according to manufacturer’s
instructions. Detection of outliers, relative expression levels
of each gene-of-interest ([GOI]; ΔCq(GOI) = 20 – Cq (GOI)
+ [Cq (CALM2) + Cq (OAZ1) + Cq (RPL37 A)]/3) as well
as EP scores were calculated as described previously
using a web-based implementation to process analytical
PCR results into EP scores which can be found at: http://
forschung.medizin.uni-mainz.de/epreport/ [1].
Assessment of limit of blank (LoB), limit of detection
(LoD), linear dynamic range and PCR efficiency
LoB, defined as the 5%-percentile of the distribution of
Cq-values measured in a blank sample without analyte,
was calculated as described in supplemental data (see
Additional file 1) [16]. LoD was defined as the amount
of the reference RNA or DNA at which the Cq value is
below the LoB with a probability of 95%. Since an abso-
lute quantification of the 12 different targets in total
RNA or DNA from FFPE tumors was not possible LoD
was referred to the fold-dilution of the reference nucleic
acid and to the respective Cq value as a surrogate for the
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LoD and linear dynamic range, four independent series
of 20 gravimetrically controlled serial 1:2 dilutions (log2)
were generated from a pooled RNA sample (DNA
sample for HBB PCR) from FFPE tissue resulting in 21
different concentrations [16-18]. Details about the dilu-
tion series and assessment of LoD and linear range are
described in supplemental data (see Additional file 1).
For each single PCR assay the linear dynamic range was
determined by fitting a linear, quadratic, or cubic model.
A maximum deviation from linearity of 1 Ct value was
accepted. After assessing the linear dynamic range, the
PCR efficiency was calculated by E = (2-1/m-1) x 100%
where m is the slope of the linear regression model.Assessment of precision
The precision experiment was designed according to
CLSI guidelines [13] and evaluated following ISO 5725-2
and NCCLS EP5-A2 [19,20]. The following variables
were included: day (n=11), day time (n=2), PCR instru-
ment (n=4), position of sample on 96-well EndoPredict
plate (n=2), lot of EndoPredict plate (n=4), lot of
enzyme/master mix (n=2), and operator (n=3). The
experiment was performed during 28 calendar days
including a 5 working days familiarization period at the
beginning. Three different RNAs were used as test
samples: One sample from a tumor with a low EP score
(2.4), one with a high EP score (13.5) and one at the
decision point between low and high risk (4.9). RNA was
isolated from several sections and pooled for each tumor
to have sufficient RNA for the whole precision experi-
ment. In addition to the test samples, one quality control
sample (Stratagene qPCR Human Reference Total RNA)
was analyzed in each run.
For verification in the laboratory of Charité as a repre-
sentative routine laboratory an abbreviated precision
experiment with fewer variables was performed: day
(n=5), day time (n=2), position of sample on 96-well
EndoPredict plate (n=2), lot of enzyme/master mix
(n=2), and operator (n=2).
Variable noise, replicate noise and total noise was
calculated using univariate N-way analysis of variance
(ANOVA) and indicated as standard deviations [18] as
described in detail in supplemental data (see Additional
file 1).Statistics
For EP scores 95% confidence intervals (CI) were calcu-
lated as described [1]. For comparison of EP test results
between two different laboratories Pearson correlation
coefficient (R2) was calculated and agreement of
measurements were analyzed as described by Bland &
Altman [21].Results
Limit of blank, limit of detection, linear dynamic range
and PCR efficiency
For each of the 12 genes the analytical performance of
the RT-qPCR assays was assessed. For a type I error of
5% the LoB was at a Cq value of 40 for all genes (Table 1).
The LoD of the 12 assays ranged from Cq 35.1 to 37.2
(Table 1; supplemental data Figure 1 [see Additional file 1]).
All 11 RNA-specific assays were linear up to dilutions
between 2-9 and 2-16 corresponding to Cq values
between 35.1 and 37.2 (Table 1; supplemental data
Figure 2 [see Additional file 1]). Amplification efficiencies
ranged from 76% to 101% with a mean efficiency of 88%
(Table 1). The DNA-specific HBB PCR assay was
linear up to a Cq value of 35.3 (dilution: 2
-8) and had
an efficiency of 75%.
Input range
For a multigene expression test it is essential to deter-
mine the acceptable range of input RNA within which
the assay yields accurate results for all variants tested
[13]. For that purpose a set of six breast cancer samples
with different EP scores ranging from 2.5 to 11.5 were
selected. Following RNA isolation different amounts of
sample per reaction were assessed by the EndoPredict
assay. The average of the Cq values of the three reference
genes (Cq-ARG) was used as surrogate for mRNA input.
Although an increase of the 95% CI was observed above
Cq-ARGs of 26 the EP score did not significantly change
within an RNA input range of Cq-ARG between 20.5
and 28 (Figure 2A). Analysis of the individual genes
showed that STC2, IL6ST, and BIRC5 were the first
analytes to drop out as the RNA amount was decreased
(data not shown). In order to calibrate the Cq-ARG
values to total RNA concentrations the amount of total
RNA in a set of 45 samples was assessed (Figure 2B).
The range of input RNA concentration without consid-
erable change of the EP score was between 0.16 and 18.5
ng/μl corresponding to a about 100-fold difference.
Precision
Precision of the multigene expression assay was evalu-
ated under various stipulated operating conditions
including day, day time, PCR instrument, position of the
sample on the EndoPredict plate, plate lot, reagent lots,
and operators and using three different test RNA sam-
ples from FFPE breast cancer tissue with a low EP score
(2.4), a high EP score (13.5), and an EP score close to
the decision point (4.9). In total, 160 EndoPredict tests
(Figure 2C) were performed consisting of 5270 measured
Cq values of the RNA-specific PCR assays and 1280 ΔCq
values of the 8 genes-of-interest. The overall variability
(standard deviation [SD]) of the EP scores was 0.15
(Table 2), which is 1% of the total EP score range
Table 1 LoB, LoD, linear dynamic range, PCR efficiency of the 12 PCR assays included in EndoPredict
Gene LoB LoD [Cq value] Linear range [log2 dilution step] Linear range [Cq value] Efficiency [%]
AZGP1 40.0 35.6 (34.2 - 36.4) −13.1 to 0 35.6 to 20.5 81.9 (80.3 - 83.6)
CALM2 40.0 35.4 (34.3 - 36.0) −14.0 to 0 35.4 to 21.6 101.4 (99.8 - 103.2)
BIRC5 40.0 36.3 (35.4 - 36.9) −9.1 to 0 36.3 to 26.7 93.3 (90.5 - 96.2)
DHCR7 40.0 36.3 (35.4 - 36.8) −10.9 to 0 36.3 to 24.5 89.9 (87.6 - 92.3)
IL6ST 40.0 36.8 (35.7 - 37.5) −11.5 to 0 36.8 to 23.3 80.7 (78.8 - 82.7)
MGP 40.0 37.2 (35.2 - 38.2) −13.9 to 0 37.2 to 20.2 76.3 (74.4 - 78.2)
OAZ1 40.0 36.6 (35.5 - 37.2) −12.9 to 0 36.6 to 22.6 89.0 (87.6 - 90.4)
RBBP8 40.0 35.6 (34.7 - 36.1) −9.4 to 0 35.6 to 25.9 96.3 (93.2 - 99.6)
STC2 40.0 35.1 (34.2 - 35.7) −9.9 to 0 35.1 to 24.0 85.2 (82.6 - 87.9)
UBE2C 40.0 36.0 (34.9 - 36.7) −10.1 to 0 36.0 to 24.4 83.3 (81.1 - 85.7)
RPL37A 40.0 36.0 (34.5 - 36.7) −16.4 to 0 36.0 to 19.0 94.5 (92.9 - 96.1)
HBBV2 40.0 35.3 (33.6 - 36.2) −7.6 to 0 35.3 to 25.9 75.4 (70.1 - 81.6)
95% confidence intervals are indicated in brackets. For linear range a maximum deviation from linearity of 1 Ct value was accepted.
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the test. Interestingly, the major part of the total noise
(SD 0.14) was caused by the replicate-to-replicate noise
of the PCR assays (repeatability) and was not associated
with different operating conditions (reproducibility). The
same was true for the variations of Cq or ΔCq values
which showed overall standard deviations (total noise) of
0.20 and 0.12, respectively (Table 2). Repeatability and
reproducibility of the individual gene-specific PCR
assays are summarized in supplemental data Tables 1&2
(see Additional file 1).
Verification of performance characteristics in an
independent laboratory
The performance characteristics of the EndoPredict
assay were verified in a routine laboratory at the Charité
in Berlin to confirm that the test performs to specifications
also in a routine diagnostic laboratory. The parameters
verified were efficiency of the single PCR assays, precision,
input range, and analytical accuracy with respect to refer-
ence values.
For assessment of linear range and efficiency two inde-
pendent series of seven 1:2 dilutions of the reference
RNA pools and DNA from FFPE tissue were generated.
Each nucleic acid concentration was assessed four times.
The 11 RNA-specific assays were linear over the whole
range of concentrations analyzed (dilutions up to 2-7),
the HBB assay up to dilution step 2-6 (Table 3). On aver-
age the efficiencies of the RNA assays were 84% and
ranged from 78% to 98% which was within the pre-
specified reference limits (Table 3). The efficiency of the
HBB assay was 79%. Assessing the EP scores in each
dilution step showed stable values down to an input
RNA of Cq-ARG of 28 verifying the results of the studies
at Sividon (Figure 3A).Moreover, precision of the EndoPredict test was veri-
fied assessing the impact of the day, day time, the pos-
ition of the sample on the 96-well EndoPredict plate, the
reagent lot, and the operator on the reproducibility of
the assay. The two RNAs from the tumors with the low
and the high EP score were analyzed using the EndoPredict
test resulting in 659 Cq values, 160 ΔCq values and 20 EP
scores. The total variation (standard deviation) of the EP
scores was 0.18 (Table 4) and thus almost identical to the
variation of the EP scores generated at Sividon (Table 2).
In the Charité laboratory variable noise induced by oper-
ating conditions had a similar impact on total noise as
replicate noise. Standard deviations of Cq values and
ΔCq values were 0.24 and 0.14 and therefore similar to
those at Sividon.
Finally, the analytical accuracy of the EndoPredict
assay performed in the Charité laboratory was examined.
For that purpose, ten breast tumor samples were
selected and the EP scores were determined at Sividon.
These pre-determined scores ranging from 3.3 to 11.0
were used as reference values. Five of the cases were
very close to the predefined cutoff of the EP score. The
pre-specified aim for the verification study at Charité
was that the difference between the EP score at Charité
and the reference EP score was below 1.0 EP units for at
least 9 of 10 samples. Charité received a 10 μm tissue
section of each of the ten tumors, isolated RNA and per-
formed the EndoPredict test. The aim of this verification
study was achieved as the largest deviation from the
reference value was 0.36 score units with a mean devi-
ation of 0.15 (Figure 3B). Using the cutoff value of 5 to
classify a sample in low or high risk of distant metastasis
the concordance of classifications between Charité and
Sividon was 90%. The discrepant sample was very close















































Figure 2 RNA input range and reproducibility of EndoPredict.
(A) EP scores depending on amount of input RNA. RNAs from 6
different FFPE samples were diluted and EP scores were assessed
dependent on RNA input (Cq-ARG as surrogate marker). 95%
confidence intervals (CI) of EP scores calculated from the noise
model are indicated. (B) Correlation between Cq-ARG and total RNA
concentration assessed by RIBOGREEN assay. Lower RNA input limit
is indicated by dotted lines. (C) Reproducibility of 160 EP scores
assessed in three different RNA samples (low risk, close to the
decision point, high risk) over time (11 different working days
distributed over 21 calendar days). Individual EP measurement
results are indicated by dots.
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was found.
Discussion
In this study, we showed by means of a defined analytical
validation and verification process developed according to
the CLSI guidelines that the RT-qPCR-based EndoPredict
multianalyte gene expression test is a robust test that can
be performed reproducibly and accurately. The resulting
performance characteristics therefore meet the require-
ments needed for a diagnostic test. Moreover, we verified
that a comparable performance with respect to assay
efficiency, precision, and accuracy can also be achieved in a
routine molecular diagnostic laboratory. In addition, this
study provides the specifications for analytical verification
of EndoPredict in molecular pathological laboratories.
Successful clinical validation of the EndoPredict score
in two large clinical trials was published previously [1]
resulting in a level of evidence of 1B according to the
classification for prognostic biomarkers that has beenTable 2 Overall variabilities and variabilities of the EP




day 0.024 0.013 0.006
day time < 0.001 0.016 <0.001
PCR instrument 0.027 0.009 0.037
sample position 0.028 0.015 <0.001
plate lot 0.014 0.011 <0.001
reagent lot 0.085 0.027 <0.001
operator 0.003 0.014 0.043
total variable noise 0.097 0.042 0.057
replicate noise 0.176 0.111 0.136
total noise 0.201 0.119 0.147
Different operating conditions (variable noise, replicate noise, and total noise)
are indicated as standard deviations of the Cq values, ΔCq values, and the EP
scores.
Table 3 Verification of linear dynamic range and PCR







AZGP1 −7 to 0 28.5 to 20.5 82.7 (79.1 - 86.7)
CALM2 −7 to 0 28.7 to 21.5 97.6 (95.7 - 99.7)
BIRC5 −7 to 0 34.2 to 26.6 89.7 (86.4 - 93.2)
DHCR7 −7 to 0 32.4 to 24.4 83.2 (79.2 - 87.7)
IL6ST −7 to 0 31.7 to 23.3 78.0 (74.4 - 81.9)
MGP −7 to 0 28.9 to 20.0 72.3 (68.1 - 77.2)
OAZ1 −7 to 0 30.4 to 22.6 86.7 (83.6 - 90.1)
RBBP8 −7 to 0 33.5 to 25.8 87.6 (84.4 - 91.0)
STC2 −7 to 0 32.1 to 23.9 81.2 (77.7 - 85.0)
UBE2C −7 to 0 32.7 to 24.3 78.1 (74.4 - 82.2)
RPL37A −7 to 0 26.6 to 18.7 85.3 (83.1 - 87.5)
HBBV2 −6 to 0 32.7 to 25.6 79.0 (74.7 - 83.9)
95% confidence intervals are indicated in brackets. For linear range a









































Figure 3 Verification of performance data at Charité. (A) EP
scores depending on amount of input RNA assessed as Cq-ARG.
Pre-specified input limit is indicated by a dotted line. 95% CI are
given. (B) Correlation of EP scores of 10 different breast cancer FFPE
samples assessed at the molecular-pathological laboratory at the
Charité compared to reference values assessed at Sividon. The cutoff
value between low and high risk for distant metastasis is indicated
by dotted lines.
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studies which were performed within a prospective-
retrospective design showed that the test predicted
distant metastasis in patients with primary ER-positive,
HER2-negative breast cancer and provided significant
prognostic information beyond standard parameters to
assess the risk of metastasis. Both, clinical and analytical
validations of the EndoPredict multigene assay now
fulfill the recently published recommendations for trans-
lating omics-based tests from research laboratory to
clinical practice [23].
The difficulty of a comprehensive analytical validation
of a highly complex genomic multianalyte assay such as
EndoPredict is that there are no evaluation guidelines to
cover all relevant aspects. Therefore, we specified a
validation program for both, the 12 single analyte assays
and the combined multigene assay. Where applicable,
established guidelines of the CLSI as well as the MIQE
(Minimum Information for Publication of Quantitative
Real-Time PCR Experiments) guidelines were followed
[13,18]. Therefore, the analytical validation process con-
formed to the standard assay validation formats as close
as reasonably possible.
Besides EndoPredict, other prognostic multigene ex-
pression tests for patients with breast or other cancers
like MammaPrint [8], Oncotype DX Breast Cancer or
Colon Cancer Assays [9,10], or PAM50 [11,12] are
commercially available. Analytical performance character-
istics of these tests, which must be performed in reference
laboratories, were published only for some tests such as
MammaPrint [24] or the two Oncotype DX assays [25,26].
Here, we assessed the analytical performance data ofEndoPredict and provide further evidence that EndoPredict
is suitable for decentralized testing in specialized molecular
pathological laboratories which is a unique feature not
shown for the other RNA-based multigene expression tests.
On one hand this conclusion is supported by the verifica-
tion of the performance characteristics and the accuracy of
the measurements in a routine laboratory. On the other
hand, the data of the precision study in two different
laboratories showed a total variation (standard deviation) of
Table 4 Verification of overall variability and variability
of the EP scores, Cq values, and normalized ΔCq values at




day 0.034 0.032 0.093
day time 0.062 0.073 0.074
sample position <0.001 0.016 <0.001
reagent lot 0.182 0.031 <0.001
operator 0.035 0.073 0.041
total variable noise 0.198 0.114 0.125
replicate noise 0.131 0.085 0.126
total noise 0.238 0.142 0.178
Different operating conditions (variable noise, replicate noise and total noise)
are indicated as standard deviations of the Cq values, ΔCq values, and the EP
scores.
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1% of the total EP score range from 0 to 15. This is similar
to the variation of the Oncotype DX Breast Cancer Assay
performed in one centralized company laboratory [25].
Interestingly, the main factor influencing total noise was
not one of the individual variables tested, such as operator,
PCR machine, day, day-time, or reagent lots but rather
replicate-to-replicate noise which is assumed to be caused
by PCR technique-inherent noise. In order to account for
PCR-inherent noise the EndoPredict algorithm includes a
“noise model” estimating the acceptable variance of
replicate noise with respect to the Cq value. On this
basis outlier elimination is accomplished [1]; one of its
principal requirements is triplicate measurements.
Robust performance of the EndoPredict test in a
decentralized setting was also shown in a successful
prospective proficiency testing study including seven
different molecular pathology laboratories [2]. In this
study, 69 out of 70 EndoPredict measurements were
within the pre-specified range, 100% of the samples were
correctly classified as low or high risk of metastasis, and the
total variation (standard deviation) of all measurements was
0.25 units, corresponding to 1.7% of the whole range of the
EP score. The slightly larger total variation in comparison
to the results from the analytical precision study where
large RNA pools were used might be due to the fact that in
the proficiency testing the participants received tissue
sections and not RNA for testing, thus including variation
induced by tumor heterogeneity.
A recent study assessed the variability of Ki-67 immu-
nohistochemistry, which is a standard antibody-based
diagnostic test in pathology used for treatment decision
making in luminal breast cancer [27]. The authors found
standard deviations of Ki-67 results obtained by 15pathologists on centrally stained slides of three breast
carcinomas ranging from 21.7% to 24.1%. Interestingly,
even clear guidelines how to assess Ki-67 could not
improve variability.
Although our results might suggest a higher reproducibil-
ity of the PCR-based test using standardized instruments
and reagents, it is important to know that the pathological
laboratories involved in this technical verification study as
well in the proficiency testing of EndoPredict were highly
experienced in molecular work. Therefore, the results might
be different in laboratories with less molecular diagnostic
experience and ongoing quality control by periodical round
robin tests might be reasonable.
A critical issue for accurate results from any diagnostic
assay is the use of optimal sample material. For this
validation study optimal FFPE tumor material was selected
by experienced pathologists on the basis of adjacent
HE-stained tissue slides. Hence, in order to obtain
high-quality EndoPredict results an expert pathological
evaluation of the tissue specimens is mandatory. Moreover,
a highly standardized method for RNA isolation as used in
this validation study and in the EndoPredict proficiency
testing is necessary. In this study, the validation of the RNA
extraction method was not a primary aim. The silica-coated
magnetic beads-based method used and recommended for
EndoPredict was thoroughly validated in previous studies
showing a reliable analysis of RNA transcript levels by
RT-qPCR in FFPE tissue [4-6]. Finally, the PCR platform
used in this validation study was validated and CE-
marked for diagnostic purposes by the manufacturer. It
also supports robust performance of the EndoPredict
assay. Therefore, change of isolation method, enzymes,
and PCR platform might alter performance characteristics
of this multianalyte assay.
Conclusions
In conclusion, this study provides the analytical perform-
ance characteristics of the EndoPredict breast cancer prog-
nosis multigene expression assay. They can be used as a
reference for analytical verification of the test in molecular
pathological laboratories. Moreover, the study shows a
robust and reliable performance of the test and provides
conclusive evidence that RT-qPCR-based quantitative mul-
tigene expression analysis of FFPE tissue samples is feasible
in a decentral setting in molecular pathological laboratories.
This is a major technical advance in comparison with
existing prognostic multigene expression tests which are
performed in central reference laboratories. Together with
the clinical validation studies and the prospective analytical
proficiency testing program with seven different molecular
pathological laboratories these results provide the basis for
the application of EndoPredict as a test to assess prognosis
under endocrine therapy in clinical decision making in a
decentralized environment.
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